Compare GeneDx Holdings Corp (WGS) vs TeraWulf Inc (WULF) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
GeneDx Holdings Corp vs TeraWulf Inc — how do they compare? GeneDx Holdings Corp trades at $67.29 (market cap $2.02B), while TeraWulf Inc trades at $13.81 (market cap $6.81B). The key difference: TeraWulf Inc is far larger — about 3.4× GeneDx Holdings Corp's market cap, and GeneDx Holdings Corp is more actively traded (734,640 versus 45,841,998). Which is the better fit depends on your goals — on Pluang, investors hold GeneDx Holdings Corp for 19 Days and TeraWulf Inc for 17 Days on average.
| WGS | WULF | |
|---|---|---|
Market Cap | $2.02B | $6.81B |
Volume | 734,640 | 45,841,998 |
Sector | Health | Financials |
52-Week High | $167.51 | $28.98 |
52-Week Low | $34.51 | $10.99 |
Typical Hold Time | 19 Days | 17 Days |
Enterprise Value | $2.05B | $9.43B |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
GeneDx (WGS) trades at $68.09, down 0.64% today, with a bearish technical signal despite bullish oscillators showing oversold conditions. The company reported mixed Q2 2026 results with revenue beating expectations but negative profitability metrics, including a -23.4% net income margin. Recent news highlights product launches and industry recognition, while analyst consensus remains strongly bullish with a $81 price target.
The stock presents a growth opportunity in genomic testing with strong analyst support, but faces significant execution risks from persistent losses and high valuation multiples. Key catalysts include continued revenue growth and path to profitability, while risks include competitive pressures and cash flow challenges from negative operating cash flow in 2026.
TeraWulf (WULF) trades at $13.77, down 4.38% on the day, amid a bearish technical signal and weak fundamentals. The company reported a net loss of $661.42 million in 2025 with a negative net income margin of -1,179.94%, while revenue was $168.46 million. Recent news highlights volatility tied to AI infrastructure trends, with shares reacting to sector-wide moves and analyst coverage initiations.
Despite unanimous analyst buy ratings and a $34.92 consensus price target implying significant upside, high valuation ratios and persistent losses pose substantial risks. Investment appeal hinges on successful execution of the AI data center strategy, but cash flow challenges and competitive pressures require careful monitoring.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
Top news
Latest headlines on both assets
Top news
Latest headlines on both assets
About GeneDx Holdings Corp
GeneDx is a patient-centered health intelligence company that specializes in transforming healthcare through the application of genomics. It combines advanced technology with one of the world's largest rare disease genomic datasets to provide clinical-grade exome and genome sequencing, enabling precise and rapid diagnosis for patients with complex medical conditions.
Read more on WGS →About TeraWulf Inc
TeraWulf develops, owns, and operates fully integrated digital infrastructure powered by predominantly zero-carbon energy. It utilizes a hybrid business model that combines industrial-scale Bitcoin mining with high-performance computing (HPC) and AI hosting, leveraging sustainable power sources like nuclear and hydroelectric to deliver low-cost, energy-efficient data center solutions.
Read more on WULF →
